Intracellular News and Research

RSS

Velcade major improvement over standard therapy for relapsed multiple myeloma

Early results from a major, international Phase III clinical trial decisively show that recurrent multiple myeloma is more effectively treated with the drug bortezomib (trade name: Velcade TM) than with dexamethasone, a drug that for decades has been the standard therapy for relapsed disease, researchers at Dana-Farber Cancer Institute report.

6 Jun 2004

International research team have decoded the genetic blueprint of the tularemia (rabbit fever) bacterium

Two teams of researchers, one based in the United States and the other in Europe, have decoded the genetic blueprint of the tularemia (rabbit fever) bacterium, a highly infectious human and animal pathogen.

6 May 2004

Morphine does not alleviate acute pain in preterm neonates

Preterm neonates undergo many painful procedures as part of their standard care in the Neonatal Intensive Care Unit (NICU). Preterm babies are able to experience pain and indeed are highly sensitive to it.

2 May 2004

Experimental smallpox DNA vaccine

In the first successful study of its kind, scientists have shown that a DNA-based vaccine for smallpox can protect nonhuman primates from monkeypox, a disease that resembles smallpox in humans.

27 Apr 2004

Curry offers possible protection against Alzheimer’s disease

A new study has found that curry, a common and popular cooking additive, could be an effective enhancer of an enzyme that protects the brain against oxidative conditions.

19 Apr 2004

Scientists have discovered that a non-genetic molecular process can effect cell behaviour

Genetic mutations, sudden, random and usually harmful changes to the structure of a gene, are only one factor that determines the ultimate fate of a cell. Chicago scientists have discovered that a non-genetic molecular process also can play a role, and that experimenters can influence this process in bacteria, they report in the April 1 issue of the journal Nature.

1 Apr 2004

Scientists seek cause for what makes good cell go bad

Genetic mutations--sudden, random and usually harmful changes to the structure of a gene--are only one factor that determines the ultimate fate of a cell. Chicago scientists have discovered that a non-genetic molecular process also can play a role, and that experimenters can influence this process in bacteria, they report in the April 1 issue of the journal Nature.

31 Mar 2004

Novel vaccine technology to suppress the growth of certain tumors

MedImmune, Inc. and Cerus Corporation have announced preclinical results demonstrating the effectiveness of a novel therapeutic vaccine technology in suppressing the growth of certain tumors.

From Baxter International Inc. 29 Mar 2004

p53 protein peptide stops cancer in its tracks

Researchers have dreamed of thwarting cancer by using proteins that halt cell growth and kill the tumor. In theory, the approach should work. In practice, however, scientists have not had an easy time of getting tumor suppressor proteins into cells where they can block growth effectively.

26 Mar 2004

New Research Information on Tumor Necrosis Therapy

Researchers for Peregrine Pharmaceuticals presented today at the Strategic Research Institute’s Clinical-Stage Product Partnering Summit in La Jolla, CA a summary of clinical experience with Tumor Necrosis Therapy (TNT). The TNT technology is being developed in the U.S. and Europe by Peregrine under the trade name Cotara™. Over 200 patients have been treated with TNT world-wide and a TNT product has been approved to treat grade III or IV advanced lung cancer in the People’s Republic of China. A Cotara registration study for brain cancer has been approved by the U.S. Food and Drug Administration, and a Phase I colorectal cancer study is on-going at Stanford University Medical Center.

25 Mar 2004

New research may help treatment of Norrie disease and familial exudative vitreoretinopathy (FEVR)

Researchers have discovered that genetic mutations underlying two inherited eye disorders arise in different components of a single intracellular signaling pathway that is responsible for development of blood vessels in the eye.

22 Mar 2004

Forward step in treatment of Allergic Rhinitis

Rigel Pharmaceuticals, Inc. has announced the presentation of clinical data for R112, the company’s lead candidate for the treatment of allergic rhinitis, during a poster session at the annual meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) in San Francisco, CA. The phase I/II single dose trial demonstrated that R112 was well tolerated and showed favorable biological effects.

22 Mar 2004